Royalty Pharma plc (RPRX) Reports Q2 Revenue of $555 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Royalty Pharma Reports Second Quarter 2021 Results
August 11, 2021 7:00 AM EDTStrong growth in net cash provided by operating activities (GAAP) and Adjusted Cash Flow(2)
Announced transactions of up to $2.8 billion in 2021, including $2.1 billion* in upfront paymentsIncreased 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,080 to $2,120 million
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(1) (a... More
